CLINUVEL Pharmaceuticals (ASX:CUV): SCENESSE, FY26 Earnings and Pipeline Milestones

Aditi Sarkar

12 November 2026 04:39 PM AEDT

CLINUVEL Pharmaceuticals (ASX:CUV): SCENESSE, FY26 Earnings and Pipeline Milestones

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CLINUVEL (ASX:CUV) reported AUD 94.0 million of FY26 revenue.
FY26 profit before tax reached AUD 47.7 million.
The group disclosed AUD 252.1 million in cash reserves on its stated measure.
CLINUVEL shares gained 0.53% to AUD 7.59 on 12 November 2026.

CLINUVEL Pharmaceuticals Limited (ASX:CUV) develops and commercialises pharmaceutical treatments focused on photoprotection and related medical applications. Its established therapy SCENESSE is used for eligible patients with erythropoietic protoporphyria, a disorder associated with intolerance to light. On 12 November 2026, CLINUVEL shares changed hands at AUD 7.59, representing a session rise of 0.53%. Its 2026 Annual Report sets out commercial results, development programmes and regulatory activities, including an expansion of geographic access to SCENESSE.

SCENESSE and the Commercial Business

CLINUVEL (ASX:CUV) centres its marketed pharmaceutical activities on SCENESSE, an afamelanotide product for patients with erythropoietic protoporphyria. The company’s commercial Economics are shaped by treatment-centre participation, patient access, regulatory approvals and the frequency of administration. These elements matter because eligible patient numbers and the availability of authorised treatment sites influence how the medicine is supplied.

The company reported that global EPP patient numbers, treatment centres and dosage frequency increased during FY26. CLINUVEL also said that Health Canada granted a Notice of Compliance in July 2026, allowing SCENESSE to be marketed to eligible Canadian EPP patients. Regulatory authorisation creates a route to supply, but does not on its own quantify uptake or commercial Revenue from Canada.

2026 Regulatory and Development Activity

During 2026, CLINUVEL (ASX:CUV) continued evaluating treatments beyond its existing commercial medicine. The annual report refers to CUV105 case reports involving repigmentation, with twelve cases presented at scientific conferences. Such observations are distinct from final trial results and cannot establish regulatory approval or broad treatment efficacy.

The company also reported validation of the Manufacturing process for NEURACTHEL Instant while progressing towards a European regulatory filing. Manufacturing validation and a prospective regulatory submission are separate development steps. Neither should be described as an approval to market. The annual report identifies CUV107 commencement in the second half of 2026 as a development objective and full CUV105 results in the first half of 2027 as a forthcoming event.

FY26 Financial Position and Business Context

CLINUVEL (ASX:CUV) reported FY26 revenue of AUD 94.0 million and profit before tax of AUD 47.7 million. The company stated cash reserves of AUD 252.1 million under a non-IFRS measure. That measure should be interpreted as presented in its annual report rather than automatically equated to a statutory cash balance or unrestricted funds available for every possible use.

The annual report also records a tenth consecutive year of profit and ninth consecutive annual dividend. These achievements describe reported historical outcomes; they do not imply any future Dividend rate or financial result. The combination of commercial treatment revenue and research expenditure means changes in patient access, development spending and operational costs can affect future periods differently.

Risks and Milestones Ahead

CLINUVEL (ASX:CUV) faces exposure to the continued commercial performance of SCENESSE, the terms of reimbursement and access, product manufacturing requirements and the timing of regulatory assessments. A clinical development programme requires further evidence, and early findings must not be treated as proof of final efficacy or approval.

Milestones identified in the FY27 outlook include expansion of the VALLAURIX research, development and innovation centre, progress on CUV105 and CUV107, and a planned PhotoCosmetics M-lines launch in the second half of 2027. These remain company-stated plans and may change with development, operational or regulatory conditions.

Key Insights

CLINUVEL (ASX:CUV) enters its next reporting period with an established SCENESSE commercial operation, reported FY26 pretax profit and substantial stated cash reserves. Canadian authorisation and work across other programmes add milestones to monitor. The distinction between commercial revenue, case reports, planned trials and regulatory outcomes remains central to interpreting the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.